Motric Bio is an Aditum Bio portfolio company founded in November 2021 following the successful in-licensing of our lead product candidate, MTR-601, a selective myosin-2 inhibitor of fast skeletal muscle, from Motorpharma, Ltd. We are rapidly advancing this novel therapy with the first human studies planned to start in the first half of 2023.